

Scholar-in-Training Awards

The AACR is proud to offer Scholar-in-Training Awards to enable the participation of meritorious early-career scientists at the Annual Meeting 2015. Since its inception in 1986, the AACR Annual Meeting Scholar-in-Training Award program has provided more than 4,700 grants to young investigators and has received support from more than 40 cancer research foundations, corporations, individuals and other organizations dedicated to the fight against cancer. This year, twelve organizations generously provided the funding to support this program.

The names and affiliations of the 2015 Scholar-in-Training Award recipients, along with the numbers and titles of their presentations, are listed below.

2015 AACR-Aflac, Inc. Scholar-in-Training Awards

For AACR Associate Members presenting outstanding proffered papers at the Annual Meeting 2015. Support for AACR Scholar-in-Training Awards is part of Aflac's generous support of activities for early-career scientists within the AACR.

Thomas U. Ahearn, PhD, MPH, Harvard T. H. Chan School of Public Health, Boston, MA. **Abstract 939**. A prospective investigation of PTEN loss and ERG expression in lethal prostate cancer.

Brian J. Altman, PhD, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA. **Abstract 4708**. Mammalian glutamine metabolism controls circadian rhythm through regulation of reactive oxygen species.

Sarah R. Amend, PhD, Brady Urological Institute, Johns Hopkins University, Baltimore, MD. **Abstract 2884**. Tumor-driven eutrophication of the tumor ecosystem selects for cancer cell clones that overcome evolutionary inertia leading to increased metastatic capacity.

Monica E. Burgett, BS, Cleveland Clinic Lerner Research Institute, Cleveland, OH. **Abstract 4178**. L1CAM and integrin $\alpha\beta3$ mediate direct cell contact between cancer stem cells and endothelial cells: Promotion of endothelial cell migration and survival.

Laura Cato, PhD, Dana-Farber Cancer Institute, Boston, MA. **Abstract 4677**. Control of androgen receptor function by the genomic action of the cochaperone Bag-1L.

Noura J. Choudhury, BSc, University of Chicago Pritzker School of Medicine, Chicago, IL. **Abstract 4899**. Tumor T-cell receptor (TCR) diversity elucidates the immune response to genetic alterations of muscle-invasive bladder cancer.

Maria A. Cortez, PhD, University of Texas MD Anderson Cancer Center, Houston, TX. **Abstract 2875**. p53 regulation of PDL1 is mediated through miR-34a.

Ha X. Dang, PhD, Washington University in St. Louis, St. Louis, MO. **Abstract 4109**. Clonal evolution of metastatic colorectal cancer.

Yaiza Del Pozo Martin, MSc, London Research Institute - Cancer Research UK, London, United Kingdom. **Abstract 4723**. Mesenchymal status promotes metastatic colonization via a cancer cell-stroma crosstalk which uncouples EMT and stemness.

Amit G. Deshwar, MAsc, University of Toronto, Toronto, Canada. **Abstract 4865**. PhyloSpan: using multi-mutation reads to resolve subclonal architectures from heterogeneous tumor samples.

Gregory S. Ducker, PhD, Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton, NJ. **Abstract 4709**. Compartmental flexibility in mammalian folate metabolism.

Mohammad Fallahi-Sichani, PhD, Harvard Medical School, Boston, MA. **Abstract 3744**. Single-cell analysis of adaptive resistance and fractional responses of melanoma cells to RAF/MEK inhibition.

Christina Ferrer, BS, Drexel University College of Medicine, Philadelphia, PA. **Abstract 518**. O-GlcNAcylation regulates breast cancer cell invasion via the NAD⁺-dependent deacetylase SIRT1.

Rachana Garg, PhD, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA. **Abstract 799**. Protein kinase C ϵ cooperates with Pten deficiency to regulate NF- κ B pathway in prostate cancer progression.

Mark L. Hanke, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA. **Abstract 3182**. Reduced tumor burden and mortality in IL-17RA-deficient EGFR mutant mice.

Mohammad B. Hossain, PhD, University of Texas MD Anderson Cancer Center, Houston, TX. **Abstract 3298**. ABL1 is required for Tie2-mediated DNA repair in brain tumor stem cells.

Menggui Huang, PhD, University of Pennsylvania, Philadelphia, PA. **Abstract 5222**. Endothelial plasticity generates aberrant angiogenesis and therapy resistance in glioblastoma.

Alyssa A. Leystra, BS, University of Wisconsin-Madison, Madison, WI. **Abstract 4143**. Discrete clones cooperate to promote tumor progression through a non-cell-autonomous mechanism in intestinal cancers.

Adrienne H. Long, BS, Northwestern University and NIH, Bethesda, MD. **Abstract 4702**. 4-1BB costimulation ameliorates exhaustion and prolongs in vivo persistence of chimeric antigen receptor (CAR) expressing T cells.

Anisha Mathur, BTech, Ohio State University, Columbus, OH. **Abstract 985**. Stromal PDGFR- α activation stalls mammary ductal development and increases tumorigenic potential of mammary epithelia.

Pratiek N. Matkar, MS, University of Toronto, Toronto, Canada. **Abstract 4171**. Novel regulatory role of Neuropilin-1 in endothelial to mesenchymal transition as a potential source of carcinoma associated fibroblasts.

Brett A. Morris, BA, University of Wisconsin-Madison, Madison, WI. **Abstract 332**. Extracellular matrix stiffness regulates metabolic state in metastatic, but not quiescent, breast carcinoma cells.

Tea Pemovska, MSc, Institute for Molecular Medicine Finland (FIMM), Helsinki, Finland. **Abstract 676**. Axitinib targets gatekeeper-mutant BCR-ABL1(T315I)-driven leukemia in a distinct and selective fashion.

Karsten A. Piones, MD, PhD, New York University School of Medicine, New York, NY. **Abstract 2856**. Unique changes in the TCR repertoire of tumor-infiltrating lymphocytes underlie the synergy of radiotherapy with CTLA-4 blockade.

Kristopher A. Sarosiek, PhD, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA. **Abstract 4728**. Apoptotic priming is regulated by a developmental program and predisposes children to therapy-induced toxicity.

Michael W. Schmitt, MD, PhD, University of Washington, Seattle, WA. **Abstract 2846**. Ultrasensitive detection of actionable subclones in chronic myeloid leukemia.

Gabriela Schneider, PhD, Stem Cell Institute at James Graham Brown Cancer Center, University of Louisville, Louisville, KY. **Abstract 4144**. Extracellular nucleotides and purinergic signaling as novel, underappreciated, pro-metastatic factors for human lung cancer cells.

Xi Tian, PhD, University of North Carolina-Chapel Hill, Chapel Hill, NC. **Abstract 5515**. Neoadjuvant chemoradiotherapy for rectal cancer with CRLX101, an investigational nanoparticle-drug conjugate with a camptothecin payload.

Jian Wang, PhD, National Cancer Institute, Bethesda, MD. **Abstract 923**. Nitric oxide signaling pathway as a pathogenic driver in pancreatic cancer.

2015 AACR-Bristol-Myers Squibb Oncology Scholar-in-Training Awards

Bristol-Myers Squibb Oncology has graciously donated funds to support early-career investigators who will be presenting meritorious proffered papers at the AACR Annual Meeting 2015.

Nicole M. Aiello, BS, University of Pennsylvania, Philadelphia, PA. **Abstract 5176**. Chemotherapy alters the natural history of metastatic progression.

Cindy C. Benod, PhD, Houston Methodist Research Institute, Houston, TX. **Abstract 2452**. Deorphanizing TLX: Implications for treatment of glioblastomas.

Leanne de Kock, BTech, McGill University, Montreal, Canada. **Abstract 4934**. Mosaic RNase IIIb domain DICER1 mutations in children with multiple primary tumors.

Xia Ding, PhD, National Cancer Institute, NIH, Frederick, MD. **Abstract 3019**. GIPC high expression rescues BRCA2 deficiency and promotes tumorigenesis.

Miller Huang, PhD, University of California, San Francisco, CA. **Abstract 3230**. Human stem cell-based model of MYCN-driven neuroblastoma.

Yuqi Jing, PhD, University of Miami Miller School of Medicine, Miami, FL. **Abstract 3545**. Stromal selective targeting by uPAR retargeted oncolytic measles virus inhibits breast cancer progression.

Tatiana A. Karakasheva, MS, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA. **Abstract 3175**. CD38-expressing myeloid-derived suppressor cells promote tumor growth in a murine model of esophageal cancer.

Ashish A. Kulkarni, PhD, Brigham and Women's Hospital and Harvard Medical School, Boston, MA. **Abstract 5522**. Combination of a supramolecular nanotherapeutic targeting MEK and immune checkpoint inhibitor exerts a synergistic antitumor outcome.

Jeremy J. McGuire, BA, Moffitt Cancer Center, University of South Florida, Tampa, FL. **Abstract 5072**. Mesenchymal stem cells promote osteogenesis and the evolution of apoptosis resistant bone metastatic prostate cancer.

Gaëlle M. Müller-Greven, BSc, Cleveland Clinic, Cleveland, OH. **Abstract 5226**. Glioma stem cells internalize perivascular bevacizumab via a non-canonical pathway and target it for recycling or degradation.

Juan-Yu Piao, MS, Seoul National University, Seoul, Republic of Korea. **Abstract 925**. Helicobacter pylori induces phosphorylation of STAT3 at Ser727 to promote mitophagy in gastric cancer cells.

Wei Jie Seow, ScD, National Cancer Institute, Rockville, MD. **Abstract 838**. Household stove improvement and lung cancer mortality in Xuanwei, China: A 33-years' follow-up study.

Dafydd H. Thomas, PhD, Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY. **Abstract 5084**. A multifaceted role of the Hedgehog pathway in modulating pancreatic ductal adenocarcinoma biology.

Chenxi Tian, PhD, Massachusetts Institute of Technology, Cambridge, MA. **Abstract 1819**. Profiling of extracellular matrix proteins in pancreatic ductal adenocarcinoma progression and metastasis.

Diana C. West, PhD, University of Chicago, Chicago, IL. **Abstract 4675**. GR activation modifies ER transcriptional activity and results in decreased estrogen-mediated breast cancer cell proliferation.

Mark W. Zimmerman, PhD, Dana-Farber Cancer Institute, Boston, MA. **Abstract 476**. Loss of chd5-mediated tumor suppression accelerates MYCN-driven neuroblastoma tumorigenesis in zebrafish.

2015 AACR-Gerald B. Grindey Memorial Scholar-in-Training Award

For a meritorious proffered paper in the field of preclinical science presented at the AACR Annual Meeting 2015. The late Dr. Grindey was a dedicated member of the AACR and a distinguished scientist at Eli Lilly and Company. The Gerald B. Grindey Memorial Fund was established in his honor and has been entrusted to the AACR to be used toward educational programs for early-career scientists engaged in preclinical cancer research.

Eleonora Dondossola, PhD, University of Texas MD Anderson Cancer Center, Houston, TX. **Abstract 5175**. Preclinical monitoring of prostate cancer lesions in bone by intravital multiphoton microscopy.

2015 AACR-GYRIG Scholar-in-Training Awards

Get Your Rear in Gear Philadelphia has graciously donated funds to the AACR to support early-career investigators who will be presenting meritorious proffered papers relating to colorectal cancer research at the AACR Annual Meeting 2015.

Kyle Chang, BS, University of Texas MD Anderson Cancer Center, Houston, TX. **Abstract 1087**. Genomic analysis reveals evidence of clonality in premalignant colonic polyps.

Matthew P. Hanley, BS, University of Connecticut Health Center, Farmington, CT. **Abstract 893**. Metabolomic profiling of APC Δ 14/+ mice maintained on a methyl donor deficient diet reveals alterations to methionine and fatty acid metabolism associated with cancer protection.

Yujun Hao, PhD, Case Western Reserve University, Cleveland, OH. **Abstract 1125**. Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancers.

Nicolas J. Llosa, MD, Johns Hopkins University School of Medicine, Baltimore, MD. **Abstract 451**. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints.

Yumin Oh, PhD, Johns Hopkins University School of Medicine, Baltimore, MD. **Abstract 4395**. Strategy to overcome inherent TRAIL-based therapeutic limitations.

Jessica M. Silva-Fisher, PhD, Washington University School of Medicine, St. Louis, MO. **Abstract 169**. Metastatic colorectal cancer associated long non-coding RNAs identified by transcriptome sequencing of matched primary and metastatic patient tissues.

Mingyang Song, MD, MS, Harvard T.H. Chan School of Public Health, Boston, MA. **Abstract 1879**. Prospective study of marine ω -3 polyunsaturated fatty acids and risk of colorectal cancer according to microsatellite instability.

Shubhankar Suman, PhD, Georgetown University, Washington, DC. **Abstract 807**. Parental radiation elicits increased intestinal tumorigenesis in the F1 generation of APCMin/+ and APC1638N/+ mice.

Jennifer Yang, BS, Ohio State University, Columbus, OH. **Abstract 4695**. Dual targeting of MEK and PI3K pathways can act via tumor-intrinsic mechanisms to overcome resistance and tumor-extrinsic mechanisms to modulate immunity and limit cancer cachexia.

2015 AACR-June L. Biedler Scholar-in-Training Award

For meritorious proffered papers in the field of drug resistance to be presented at the AACR Annual Meeting 2015. These awards are made possible through the Estate of Dr. June L. Biedler and shall be used in part to increase public understanding of basic cancer research. The late Dr. Biedler was a dedicated member of AACR and a distinguished scientist at Memorial Sloan Kettering Cancer Center. Dr. Biedler believed that science communication is a cornerstone to the acceleration of progress.

Christina D. Drenberg, PhD, St. Jude Children's Research Hospital, Memphis, TN. **Abstract 5464**. Host variation in OATP1B1 is associated with treatment outcome in pediatric AML.

Neel M. Fofaria, BS, Texas Tech University Health Sciences Center, Amarillo, TX. **Abstract 2679**. Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.

Shumei Kato, MD, University of Texas MD Anderson Cancer Center, Houston, TX. **Abstract 2689**. Overcoming BRAF/MEK resistance using vemurafenib with crizotinib or sorafenib in patients with BRAF-mutant advanced cancers: phase I study.

Barbara Muz, PhD, Washington University in St. Louis School of Medicine, Saint Louis, MO. **Abstract 5468**. Tirapazamine as a strategy to prevent cell dissemination and overcome drug resistance.

Randall S. Ruffner, BS, University of Pennsylvania Perelman School of Medicine and Drexel University College of Medicine, Philadelphia, PA. **Abstract 5474**. PD-L1 regulates cisplatin chemoresistance in head and neck squamous cell carcinoma.

Adam D. Swick, PhD, University of Wisconsin-Madison, Madison, WI. **Abstract 3603**. Molecular targeting of cetuximab resistant head and neck cancer.

Anna Wojtuszkiewicz, MSc, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, Netherlands. **Abstract 4437**. The relevance of aberrant FPGS splicing for ex vivo MTX resistance and clinical outcome in childhood acute lymphoblastic leukemia.

2015 AACR-Susan G. Komen® Scholar-in-Training Awards

Susan G. Komen® has graciously donated funds to the AACR to support early-career investigators who will be presenting meritorious proffered papers relating to breast cancer research at the AACR Annual Meeting 2015.

Daniel L. Abravanel, PhD, University of Pennsylvania, Philadelphia, PA. **Abstract 2894**. Notch signaling promotes survival and recurrence of dormant mammary tumor cells following HER2/neu targeted therapy.

Anja Bastian, BS, University of Oklahoma Health Sciences Center, Oklahoma City, OK. **Abstract 4451**. Novel small molecule AG311 induces tumor cell death through inhibition of mitochondrial electron transport.

Christopher P. Dravis, PhD, Salk Institute for Biological Sciences, La Jolla, CA. **Abstract 2326**. Sox10 promotes both stem-like and EMT properties in mammary cells.

Lamiaa El-Shennawy, MS, University of Illinois, Chicago, IL. **Abstract 1866**. Constitutively active NF- κ B signaling switches estrogen receptor positive breast cancer cells from a proliferative to an invasive phenotype through luminal/basal plasticity.

Sergio M. Granados-Principal, PhD, Houston Methodist Research Institute, Houston, TX. **Abstract 4086**. HMG Box Domain Containing 3 (HMGXB3), a novel TGF β -induced cancer gene that influences cancer stem cells and metastasis in triple negative breast cancer.

Christy R. Hagan, PhD, University of Minnesota, Minneapolis, MN. **Abstract 0**. Progesterone receptor promotes inflammatory gene programs in breast cancer.

Zhengyu Jiang, PhD, Fox Chase Cancer Center, Philadelphia, PA. **Abstract 2870**. A novel metastasis-associated lincRNA destabilizes tumor-suppressor mRNAs through cooperative action with NF90/ILF3 binding.

Tamer S. Kaoud, PharmD, PhD, University of Texas, Austin, TX. **Abstract 3569**. Inhibition of the TRPM7 kinase domain inhibits breast cancer cell migration and invasion and tumor metastasis.

Marilyne Kpetemey, BS, University of North Texas Health Science Center, Fort Worth, TX. **Abstract 520**. MIEN1 drives breast cancer invasion by regulating cytoskeletal dynamics.

Wing-Yee Lo, PhD, Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany. **Abstract 5483**. CYP19A1 genetic variation is a potential predictor of outcome in ER-positive postmenopausal early breast cancer patients treated with tamoxifen.

Claire I. Vanpouille-Box, PhD, New York University School of Medicine, New York, NY. **Abstract 2493**. Fractionated but not single dose radiation is an optimal adjuvant for in situ tumor vaccination.

David B. Vaught, PhD, Vanderbilt University, Nashville, TN. **Abstract 4196**. Neuregulin signaling in development and transformation of the luminal breast epithelium.

2015 AACR-MEG Scholar-in-Training Awards

For meritorious proffered papers in molecular epidemiology that will be presented at the AACR Annual Meeting 2015, supported by the Molecular Epidemiology Working Group (MEG) of the AACR. The mission of MEG is to increase knowledge about cancer and chronic disease etiology, thereby promoting the prevention and treatment of cancer, and the improvement of public health. In addition to travel support, award recipients receive a free one-year membership in the Working Group.

Anna Marie de Asis Tuazon, MS, University of California, Davis, CA. **Abstract 2739**. Transcontinental characterization of the Hispanic BRCA1 3450del4 breast cancer founder mutation.

Ericka M. Ebot, PhD, MPH, Harvard T.H. Chan School of Public Health, Boston, MA. **Abstract 4686**. Identifying obesity-linked gene expression changes in prostate cancer.

Jonathan N. Hofmann, PhD, National Cancer Institute, Bethesda, MD. **Abstract 934**. A pooled investigation of circulating adiponectin levels and risk of multiple myeloma.

2015 AACR-Millennium Pharmaceuticals, Inc. Scholar-in-Training Awards

Millennium: The Takeda Oncology Company has graciously donated funds to the AACR to support early-career investigators who will be presenting meritorious proffered papers at the AACR Annual Meeting 2015.

Asfar S. Azmi, PhD, Karmanos Cancer Institute, Wayne State University, Detroit, MI. **Abstract 4688**. Overcoming drug resistance and stemness in oncogenic kras driven pancreatic ductal adenocarcinoma through PAK4 inhibition.

Babak Behnam Azad, PhD, Johns Hopkins University, Baltimore, MD. **Abstract 4557**. Assessment of a humanized CXCR4 monoclonal antibody for therapeutic monitoring and intervention in experimental NSCLC and TNBC mouse models.

Octavian Bucur, MD, PhD, Harvard Medical School and Beth Israel Deaconess Medical Center, Boston, MA. **Abstract 3477**. 3D morphological hallmarks of breast carcinogenesis: Diagnosis of non-invasive and invasive breast cancer with Lightsheet microscopy.

Sandra Cascio, PhD, University of Pittsburgh School of Medicine, Pittsburgh, PA. **Abstract 2886**. Epigenetic regulation of MUC1 in NF-kB target gene expression of pro-inflammatory cytokines in colon cancer.

Megan A. Clarke, MHS, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD. **Abstract 5591**. Factors associated with HPV vaccine initiation among males aged 11-26 years attending outpatient clinics in the Baltimore Metro Area during 2012 - 2013.

Mauricio Da Silva Caetano, PhD, University of Texas MD Anderson Cancer Center, Houston, TX. **Abstract 413**. Targeting IL-6 as a preventive and therapeutic strategy for K-ras mutant lung cancer.

Tomas D'Alotto Moreno, MS, Instituto de Biología y Medicina Experimental, Buenos Aires, Argentina. **Abstract 465**. Progestin-driven regulatory T cells directly promote an aggressive and metastatic phenotype in triple-negative breast cancer.

Julie M. Diamond, MS, New York University School of Medicine, New York, NY. **Abstract 3329**. Ionizing radiation modifies the molecular composition of exosomes derived from breast cancer cells.

Amber J. Giles, PhD, National Institutes of Health, Bethesda, MD. **Abstract 4725**. Hematopoietic stem cell niche activation and progenitor mobilization mediate cancer-associated immunosuppression and metastasis.

Majda Haznadar, PhD, National Cancer Institute, Bethesda, MD. **Abstract 935**. Lung cancer metabolomics identifies metabolites as robust risk biomarkers.

Suleman S. Hussain, BPharm, University of Texas Health Science Center, San Antonio, TX. **Abstract 1797**. Downregulation of ribosomal protein S6 overcomes radioresistance in prostate cancer.

Song-Yi Jung, PhD, University of California, Los Angeles, CA. **Abstract 2872**. Estrogen withdrawal and breast cancer development in the presence of the KRAS-variant.

Vaishali Kapoor, PhD, Washington University in St. Louis School of Medicine, St. Louis, MO. **Abstract 1791**. Targeting radiation-inducible cell surface GRP78 using GIRLRG peptide as a novel imaging and therapeutic strategy for tumors.

Kate Lawrenson, PhD, University of South California, Los Angeles, CA. **Abstract 2783**. Common functional mechanisms underlying pleiotropy at the 19p13.1 breast and ovarian cancer susceptibility locus.

Jie Li, PhD, University of California, San Diego, La Jolla, CA. **Abstract 979**. Dynamic epigenetic regulation of glioblastoma tumorigenicity through LSD1 modulation of MYC expression.

Zhenfei Li, PhD, Cleveland Clinic Lerner Research Institute, Cleveland, OH. **Abstract 3452**. Conversion of abiraterone to D4A drives antitumor activity in castration-resistant prostate cancer.

Albert Lo, MSc, University of Pennsylvania School of Veterinary Medicine, Philadelphia, PA. **Abstract 3187**. Depleting cells expressing fibroblast activation protein disrupts tumor-promoting desmoplasia.

Catherine R. Marinac, BA, University of California, San Diego and San Diego State University, La Jolla, CA. **Abstract 1874**. Prolonged nightly fasting and breast cancer risk: findings from NHANES (2009-2010).

Somala Mohammed, MD, Baylor College of Medicine, Houston, TX. **Abstract 4703**. Improving CAR T cell function by reversing the immunosuppressive tumor microenvironment of pancreatic cancer.

Marco Napoli, PhD, University of Texas MD Anderson Cancer Center, Houston, TX. **Abstract 3975**. Pharmacologic inhibition of the $\Delta Np63/DGCR8$ axis as a novel therapeutic strategy for p53-deficient and mutant tumors.

Viralkumar M. Patel, PhD, University of Texas MD Anderson Cancer Center, Houston, TX. **Abstract 2657**. Elevated level of BCL-2 is the primary target for inhibition during duvelisib (IPI-145) therapy: ABT-199 neutralizes the resistance mechanism in chronic lymphocytic leukemia.

Elizabeth Pham, PhD, Sunnybrook Research Institute, Toronto, Canada. **Abstract 4124**. Potent anti-tumor and metastatic breast cancer efficacy of bevacizumab with CRLX101, an investigational chemotherapy nanoparticle-drug conjugate that secondarily suppresses HIF-1 α .

Jason R. Pitarresi, BS, Ohio State University Comprehensive Cancer Center, Columbus, OH. **Abstract 2883**. Genetic ablation of Smoothed in tumor-associated fibroblasts promotes pancreatic tumorigenesis.

Bernhard W. Renz, MD, Irving Cancer Research Center at Columbia University Medical Center, New York, NY. **Abstract 5079**. Parasympathetic signaling suppresses pancreatic cancer development.

Nehal R. Solanki Patel, MS, Fox Chase Cancer Center and Drexel College of Medicine, Philadelphia, PA. **Abstract 1269**. Role of ribosomal protein, Rpl22 in regulating leukemic transformation.

Na-Young Song, PhD, National Cancer Institute, Frederick, MD. **Abstract 801**. IKK α at the crossroad between inflammation, oxidative stress and lung carcinogenesis.

Kenneth C. Valkenburg, PhD, Johns Hopkins School of Medicine, Baltimore, MD. **Abstract 365**. Mobilizing prostate cancer cells from the endosteal niche by targeting the SDF-1/CXCR4 axis.

Xiaoqing Wu, PhD, University of Kansas, Lawrence, KS. **Abstract 2449**. Targeting an “undruggable” RNA-binding protein: Discovery of small molecule inhibitors of HuR for novel breast cancer therapy.

Yingjie Xu, PhD, Boston Children's Hospital and Harvard Medical School, Boston, MA. **Abstract 18**. Prohibitin 1 regulates apoptosis via its interaction with XIAP.

Emrullah Yilmaz, MD, Montefiore Medical Center, Bronx, NY. **Abstract 2023**. MYC amplification and overexpression in metastatic anaplastic thyroid cancer dictates response to therapy.

Yang Zhang, PhD, Johns Hopkins University School of Medicine, Baltimore, MD. **Abstract 2864**. Acetylation regulates TET2 stability and enzymatic activity.

2015 AACR-Pezcoller Foundation Scholar-in-Training Awards

The Pezcoller Foundation supports these awards to enhance participation in the programs and activities of the AACR by early-career investigators residing in Europe and to provide these outstanding Scholar-in-Training Awardees with an opportunity to share their research findings with the international cancer research community at the AACR Annual Meeting.

Shalini Datta, PhD, Unité Génomique Fonctionnelle des Tumeurs Solides, French Institute of Health and Medical Research (INSERM), Paris, France. **Abstract 919**. Adeno-associated virus 2 (AAV2) induces recurrent insertional mutagenesis in human hepatocellular carcinomas.

Eva A. Ebbing, MSc, Academic Medical Center (AMC), Amsterdam, Netherlands. **Abstract 350**. HER3 mediates acquired resistance to HER2-targeted therapy in esophageal adenocarcinoma.

Mahdi Fallah, MD, PhD, German Cancer Research Center (DKFZ), Heidelberg, Germany. **Abstract 2740**. Familial Hodgkin lymphoma by relationship, sex, age and histology: a joint study from five Nordic countries.

Fabrizio Miranda, PhD, Nuffield Department of Obstetrics and Gynaecology, University of Oxford, Oxford, United Kingdom. **Abstract 4111**. The salt inducible kinase 2 (SIK2) links lipid metabolism to survival of ovarian cancer metastasis.

Cristina Travelli, PhD, University of Piemonte Orientale, Novara, Italy. **Abstract 393**. Nicotinamide phosphoribosyl transferase (NAMPT) inhibitors: novel modulators of antitumor immunity.

Ghada A. Zakout, MBBS, MRCP, FRCPath, University College London (UCL) Cancer Institute, London, United Kingdom. **Abstract 3428**. Aging, telomere and TP53: a potential biological insight into the mechanistic origin of acute lymphoblastic leukemia (ALL) in the elderly.

2015 AACR-Prostate Cancer Foundation Scholar-in-Training Awards

The Prostate Cancer Foundation has graciously donated funds to the AACR to support early-career investigators who will be presenting meritorious proffered papers relating to advanced prostate cancer at the AACR Annual Meeting 2015.

Claire M. Faltermeier, BA, University of California, Los Angeles, CA. **Abstract 5183**. Identification and characterization of wild type kinases driving prostate cancer metastasis.

Yanfei Gao, PhD, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA. **Abstract 1849**. Androgen receptor transcriptionally represses genes mediating DNA synthesis and repair in prostate cancer.

Udit Singhal, BSc, University of Michigan, Ann Arbor, MI. **Abstract 2869**. SchLAP1 mediated epigenetic modifications in prostate cancer.

2015 AACR-SIC Scholar-in-Training Awards

The AACR-SIC Scholar-in-Training Awards are a partnership between the AACR and the Società Italiana di Cancerologia (SIC, the Italian Cancer Society). The AACR and SIC sponsor these awards to enhance participation by early-career investigators who are members of SIC, and to provide these outstanding Scholar-in-Training Awardees with an opportunity to share their research findings with the international cancer research community at the AACR Annual Meeting.

Antonino Bruno, PhD, Science and Technology Center, IRCCS MultiMedica, Milan, Italy. **Abstract 2367**. Tumor-infiltrating (TINKs) and tumor-associated (TANKs) natural killer cells: a new player in the inflammatory orchestration of tumor angiogenesis in colon cancer.

Paolo A. Gagliardi, PhD, Candiolo Cancer Institute, University of Turin, Candiolo, Italy. **Abstract 530**. PDK1 regulates cell migration and 3D invasion of breast tumor cells by a kinase independent mechanism.

Elena Jachetti, PhD, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. **Abstract 4054**. Mast cells contribute to T cell tolerance against prostate cancer-associated antigens favoring tumor growth.

Francesca Ricci, PhD, IRCCS- Istituto di Ricerche Farmacologiche "Mario Negri", Milan, Italy. **Abstract 4091**. Investigations on the role of epithelial-mesenchymal transition and cancer stem cells in the response to therapy in patient-derived ovarian carcinoma xenografts.

Rosanna Sestito, PhD, Regina Elena National Cancer Institute, Rome, Italy. **Abstract 3580**. Downregulated miR-30a promotes acquisition of chemoresistance by targeting endothelin A receptor in ovarian carcinoma.

2015 AACR-Warner Fund Scholar-in-Training Award

The Warner Fund has graciously donated funds to the AACR to support an early-career investigator who will be presenting a proffered paper relating to cholangiocarcinoma.

Kevin M. Sokolowski, MD, Medical College of Wisconsin, Milwaukee, WI. **Abstract 52**. Glycogen synthase kinase inhibition associated with Notch-1 reduction in cholangiocarcinoma.